Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yang, Zijiang ^a,b,c,d,e   Concannon, John ^f   Ng, Kelvin S ^a,b,c   Seyb, Kathleen ^f   Mortensen, Luke J ^g   Ranganath, Sudhir ^a,b,c,h   Gu, Fangqi ^a,b,c   Levy, Oren ^a,b,c   Tong, Zhixiang ^a,b,c   Martyn, Keir ^a,b,c   Zhao, Weian ^i,j   Lin, Charles P ^b,d   Glicksman, Marcie A ^b,f   Karp, Jeffrey M ^a,b,c  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f The Harvard Center for Neurodegeneration & Repair   (United States)

^g UNIVERSITY OF GEORGIA   (United States)

^h SIDDAGANGA INSTITUTE OF TECHNOLOGY   (India)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j University of California at Irvine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLISOQUINOLINE DERIVATIVE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; PTGS2 PROTEIN, MOUSE; TETRANDRINE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; MASS SCREENING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOLECULAR LIBRARY; MOUSE; PROCEDURES; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION;

ANIMALS; BENZYLISOQUINOLINES; CYCLOOXYGENASE 2; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MASS SCREENING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; NF-KAPPA B; RAW 264.7 CELLS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84979497707     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30263     Document Type: Article

References (71)

1. Ankrum, J. & Karp, J. M. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16, 203-209 (2010).
2. Liang, X., Ding, Y., Zhang, Y., Tse, H. F. & Lian, Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell transplantation 23, 1045-1059 (2014).
3. Islam, M. N. et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18, 759-765 (2012).
4. Ranganath, S. H., Levy, O., Inamdar, M. S. & Karp, J. M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244-258 (2012).
5. Biancone, L., Bruno, S., Deregibus, M. C., Tetta, C. & Camussi, G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 27, 3037-3042 (2012).
6. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 (2008).
7. Spaggiari, G. M., Abdelrazik, H., Becchetti, F. & Moretta, L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113, 6576-6583 (2009).
8. Prockop, D. J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 31, 2042-2046 (2013).
9. Akiyama, K. et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10, 544-555 (2012).
10. Corcione, A. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372 (2006).
11. English, K. et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 + regulatory T cells. Clinical and experimental immunology 156, 149-160 (2009).
12. Spaggiari, G. M. et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111, 1327-1333 (2008).
13. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N. & Papamichail, M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24, 74-85 (2006).
14. Ylostalo, J. H., Bartosh, T. J., Coble, K. & Prockop, D. J. Human mesenchymal stem/stromal cells cultured as spheroids are selfactivated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 30, 2283-2296 (2012).
15. Ramasamy, R. et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83, 71-76 (2007).
16. Gur-Wahnon, D., Borovsky, Z., Beyth, S., Liebergall, M. & Rachmilewitz, J. Contact-dependent induction of regulatory antigenpresenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol 35, 426-433 (2007).
17. Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS one 5, e10088 (2010).
18. Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392-402 (2013).
19. Sivanathan, K. N., Gronthos, S., Rojas-Canales, D., Thierry, B. & Coates, P. T. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem cell reviews 10, 351-375 (2014).
20. Levy, O. et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 122, e23-e32 (2013).
21. Bartosh, T. J. et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci USA 107, 13724-13729 (2010).
22. Ankrum, J. A., Dastidar, R. G., Ong, J. F., Levy, O. & Karp, J. M. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Scientific reports 4, 4645 (2014).
23. Kim, H. S. et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells 33, 1254-1266 (2015).
24. Valles, G. et al. Topographical cues regulate the crosstalk between MSCs and macrophages. Biomaterials 37, 124-133 (2015).
25. English, K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunology and cell biology 91, 19-26 (2013).
26. Najar, M. et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cellular immunology 264, 171-179 (2010).
27. Nakao, S. et al. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Molecular and cellular biochemistry 238, 11-18 (2002).
28. Pettus, B. J. et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17, 1411-1421 (2003).
29. Hegyi, B., Kudlik, G., Monostori, E. & Uher, F. Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochemical and biophysical research communications 419, 215-220 (2012).
30. Mohyeldin, A., Garzon-Muvdi, T. & Quinones-Hinojosa, A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7, 150-161 (2010).
31. Gottipamula, S., Muttigi, M. S., Kolkundkar, U. & Seetharam, R. N. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell proliferation 46, 608-627 (2013).
32. Mei, Y. B., Zhou, W. Q., Zhang, X. Y., Wei, X. J. & Feng, Z. C. Lipopolysaccharides shapes the human Wharton's jelly-derived mesenchymal stem cells in vitro. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 32, 390-401 (2013).
33. Vezina Audette, R., Lavoie-Lamoureux, A., Lavoie, J. P. & Laverty, S. Inflammatory stimuli differentially modulate the transcription of paracrine signaling molecules of equine bone marrow multipotent mesenchymal stromal cells. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society 21, 1116-1124 (2013).
34. Kotake, S. & Nanke, Y. Effect of TNFalpha on osteoblastogenesis from mesenchymal stem cells. Biochimica et biophysica acta 1840, 1209-1213 (2014).
35. Wang, C. M. et al. Co-treating mesenchymal stem cells with IL1beta and TNF-alpha increases VCAM-1 expression and improves post-ischemic myocardial function. Molecular medicine reports 10, 792-798 (2014).
36. Wu, M. et al. Serum-free media and the immunoregulatory properties of mesenchymal stem cells in vivo and in vitro. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 33, 569-580 (2014).
37. Zimmermann, J. A. & McDevitt, T. C. Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. Cytotherapy 16, 331-345 (2014).
38. Nawa, K., Ikeno, H., Matsuhashi, N., Ogasawara, T. & Otsuka, E. Discovering small molecules that inhibit adipogenesis and promote osteoblastogenesis: unique screening and Oncostatin M-like activity. Differentiation; research in biological diversity 86, 65-74 (2013).
39. Song, B. W. et al. Protein kinase C activation stimulates mesenchymal stem cell adhesion through activation of focal adhesion kinase. Cell transplantation 22, 797-809 (2013).
40. Higuchi, S., Ii, M., Zhu, P. & Ashraf, M. Delta-opioid receptor activation promotes mesenchymal stem cell survival via PKC/STAT3 signaling pathway. Circulation journal: official journal of the Japanese Circulation Society 76, 204-212 (2012).
41. 2+/PKC/ERK1/2 signal pathway. Journal of cellular biochemistry 113, 2704-2713 (2012).
42. Yu, K. R. et al. A p38 MAPK-Mediated Alteration of COX-2/PGE2 Regulates Immunomodulatory Properties in Human Mesenchymal Stem Cell Aging. PloS one 9, e102426 (2014).
43. Kwan, C. Y. & Achike, F. I. Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta pharmacologica Sinica 23, 1057-1068 (2002).
44. 2+ current in isolated nerve terminals of the rat neurohypophysis. Pflugers Archiv: European journal of physiology 421, 558-565 (1992).
45. 2+-activated chloride channel in cultured human umbilical vein endothelial cells. Acta pharmacologica Sinica 25, 327-333 (2004).
46. Ho, L. J. et al. Plant alkaloid tetrandrine downregulates IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in human peripheral blood T cell. British journal of pharmacology 143, 919-927 (2004).
47. Dang, Y. et al. Tetrandrine Suppresses Lipopolysaccharide-Induced Microglial Activation by Inhibiting NF-kappaB and ERK Signaling Pathways in BV2 Cells. PloS one 9, e102522 (2014).
48. Xue, Y., Wang, Y., Feng, D. C., Xiao, B. G. & Xu, L. Y. Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-kappaB pathway. Acta pharmacologica Sinica 29, 245-251 (2008).
49. Baldwin, A. S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual review of immunology 14, 649-683 (1996).
50. Ding, G. J. et al. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J Biol Chem 273, 28897-28905 (1998).
51. Kalinski, P. Regulation of immune responses by prostaglandin E2. Journal of immunology 188, 21-28 (2012).
52. Maggini, J. et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PloS one 5, e9252 (2010).
53. Porcheray, F. et al. Macrophage activation switching: an asset for the resolution of inflammation. Clinical and experimental immunology 142, 481-489 (2005).
54. Seebach, E., Freischmidt, H., Holschbach, J., Fellenberg, J. & Richter, W. Mesenchymal stroma cells trigger early attraction of M1 macrophages and endothelial cells into fibrin hydrogels, stimulating long bone healing without long-term engraftment. Acta biomaterialia 10, 4730-4741 (2014).
55. Levy, O. et al. A small-molecule screen for enhanced homing of systemically infused cells. Cell Rep 10, 1261-1268 (2015).
56. Ankrum, J. A., Ong, J. F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nature biotechnology 32, 252-260 (2014).
57. Teo, G. S., Yang, Z., Carman, C. V., Karp, J. M. & Lin, C. P. Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils. Stem cells 33, 265-277 (2015).
58. Pelus, L. M. & Hoggatt, J. Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function. Prostaglandins Other Lipid Mediat 96, 3-9 (2011).
59. Hoggatt, J. & Pelus, L. M. Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia 24, 1993-2002 (2010).
60. Durand, E. M. & Zon, L. I. Newly emerging roles for prostaglandin E2 regulation of hematopoiesis and hematopoietic stem cell engraftment. Curr Opin Hematol 17, 308-312 (2010).
61. You, Y. et al. Mesenchymal stromal cell-dependent reprogramming of Kupffer cells is mediated by TNF-alpha and PGE2 and is crucial for liver transplant tolerance. Immunol Res 62, 292-305 (2015).
62. Trabanelli, S. et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res 2015, 253191 (2015).
63. Hsueh, Y. C., Wu, J. M., Yu, C. K., Wu, K. K. & Hsieh, P. C. Prostaglandin E(2) promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol Med 6, 496-503 (2014).
64. Baratelli, F. et al. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2, 356-367 (2010).
65. Vo, B. T. et al. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154, 1768-1779 (2013).
66. Bourin, P. et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 15, 641-648 (2013).
67. Kern, S., Eichler, H., Stoeve, J., Kluter, H. & Bieback, K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294-1301 (2006).
68. Ankrum, J. A. et al. Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nature protocols 9, 233-245 (2014).
69. Sarkar, D., Ankrum, J. A., Teo, G. S., Carman, C. V. & Karp, J. M. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials 32, 3053-3061 (2011).
70. Gonzalez-Rey, E. & Delgado, M. Therapeutic application of mesenchymal stromal cells in murine models of inflammatory bowel disease. Methods Mol Biol 1213, 331-339 (2014).
71. Anderson, P. et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 62, 1131-1141 (2013).